Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof

Antibody molecules having specificity for human OX40

Lym-1 and Lym-2 targeted CAR cell immunotherapy

Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereof

Covalent diabodies and uses thereof

Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor

Immunoglobulin constant region Fc receptor binding agents

Radio-imaging and radio-therapy of cancer using antibodies to HAAH

Anti-TOSO chimeric antigen receptor and its use

Antibodies against OX40 and uses thereof

Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof

Methods and monitoring of treatment with a WNT pathway inhibitor

Trispecific binding proteins and methods of use

Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

Anticancer agent

Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy

CD37-binding molecules and immunoconjugates thereof

Human C-FMS antigen binding proteins

Compositions and methods for targeted immunomodulatory antibodies and fusion proteins

Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer

Therapeutic and diagnostic methods for autism spectrum disorders and other conditions

Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life

Anti-human TROP-2 antibody having an antitumor activity in vivo

Antigenic GM-CSF peptides and antibodies to GM-CSF

METHODS AND COMPOSITIONS FOR MODULATION OF OLFML3 MEDIATED ANGIOGENESIS

Targeting CLPTM1L for treatment and prevention of cancer

Antibody targeting cell surface deposited complement protein C3d and use thereof

Quantitative ligandomics for systematic identification of therapeutic ligands

Compositions and methods for targeting stromal cells for the treatment of cancer

Antibody therapeutics that bind PSMA

Means and methods for counteracting myeloproliferative or lymphoproliferative disorders

CD37-binding molecules and immunoconjugates thereof

THERAPEUTIC AGENT FOR CANCER, AND METHOD FOR DETERMINING PROGNOSIS OF CANCER

Method for Regulating Cell Proliferation

Frizzled receptor antibodies for treatment of cancer

Nanoparticle complexes of albumin, paclitaxel, and panitumumab for treatment of cancer

Recombinant production of mixtures of antibodies

Multispecific domain exchanged common variable light chain antibodies

PDK1 BINDING MOLECULES AND USES THEREOF

Neuregulin allosteric anti-HER3 antibody

Antibodies that bind OV064 and methods of use therefor

Neutralizing prolactin receptor antibody Mat3 and its therapeutic use

Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Anti-PD-1 antibodies

Antibodies to tumor endothelial marker 8

Cell penetrating conjugates and methods of use thereof

Treating basal-like genotype cancers

Antigen binding proteins that bind ErbB3

Diagnosis and treatment of cancer using anti-ITM2A antibody

Antibodies Directed To GPNMB And Uses Thereof

Human mesothelin chimeric antigen receptors and uses thereof

Anti-CD40 antibodies

Compositions and methods for inhibiting PDGFRbeta and VEGF-A

Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of thereof

Anti-Complement factor H antibodies

Nanoparticle complexes of anti-CD20 antibodies, albumin and paclitaxel

Antibodies targeting B-cell receptor complex membrane bound IGM and uses thereof

5T4-TARGETED IMMUNOFUSION MOLECULE AND METHODS

HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47

Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands

Anti-ganglioside compound for targeting cancer and generating antibodies

Engineered immunoglobulin Fc polypeptides displaying improved complement activation

Therapeutic antibodies and their uses

Chimeric antigen receptors targeting B-cell maturation antigen

Methods of treating neuropathic pain with specific binding members for NGF

Anti-pseudomonas Psl binding molecules and uses thereof

Inhibitors of type 2 vascular endothelial growth factor receptors

Anti-human mIgA antibodies capable of lysing mIgA-B lymphocytes and decreasing IgA production

CANCER BIOMARKERS AND USES THEREOF

Bispecific antigen-binding constructs targeting HER2

Anti-claudin antibodies and methods of use

Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof

Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor

Siglec-15 antibodies in treating bone loss-related disease

Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

Method of providing disease-specific binding molecules and targets

Anti-S100A7 antibodies for the treatment and diagnosis of cancer

METHOD OF MANUFACTURING INTRAVENOUS IMMUNOGLOBULIN FROM FRACTION III

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

Method for purifying antibodies

SEZ6 modulators and methods of use

Peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (RCC) and other cancers

Pulmonary administration of immunoglobulin single variable domains and constructs thereof

Anti-WT1/HLA bi-specific antibody

Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof

DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

Compositions and methods for antibodies targeting Epo

Human antibody molecules for IL-13

Method for making heteromultimeric molecules

Human IgG1 derived antibody with pro-apoptotic activity

Engineered high-affinity human t cell receptors

Engineered high-affinity human T cell receptors

Methods for using antibodies for 3′ iso-LM1 and 3′, 6′-iso-LD1tumor gangliosides

Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity

Antibody drug conjugates (ADC) that bind to FLT3 proteins

Treatment of C1013G/CXCR4-associated waldenstroöm's macroglobulinemia with an anti-CXCR4 antibody

Agents for treatment of claudin expressing cancer diseases

VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES

Human neutralizing anti-kit antibodies and uses thereof

Anti-ErbB3 antibodies

Disease therapy by inducing immune response to Trop-2 expressing cells

Antibodies for treatment of cancer expressing claudin 6

Antibodies reactive with B7-H3 and uses thereof

ANTI-PODOCALYXIN ANTIBODIES AND METHODS OF USING THE SAME

Anti-NGF antibodies and their use

Modulators and methods of use

Glycans as functional cancer targets and antibodies thereto

Antibody drug conjugates (ADC) that bind to 191P4D12 proteins

Antibody therapeutics that bind TIM3

Antibodies against CCR9 and methods of use thereof

ANTI-TIM3 ANTIBODIES AND METHODS OF USE

Antibodies specific for TROP-2 and their uses

Modulators and methods of use

Tumor necrosis factor receptor soluble factor binding (TNFRSF-binding) agents

Nanoparticle complexes of albumin, paclitaxel, and anti-VEGF antibody for treatment of cancer

Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies

Anti-PD-1 antibodies

Anti-BAFF-anti-IL-17 bispecific antibodies

Galectin-3 as immunological target

Anti-FGFR2/3 antibodies and methods using same

Combination immunotherapy for the treatment of cancer

Methods for enhancing immunosuppressive therapy by multiple administration of αβTCR-binding polypeptide

Antibodies to M-CSF

Humanized Antibody

Combination Therapy With Anti-CD74 and Anti-CD20 Antibodies Provides Enhanced Toxicity to B-Cell Diseases

Targeting intracellular target-binding determinants with intracellular antibodies

Binding molecules specific for HER3 and uses thereof

ANTI-TWEAKR ANTIBODIES AND USES THEREOF

Human anti-IL-23 antibodies, compositions, methods and uses

GLYCOENGINEERED ANTIBODY, ANTIBODY-CONJUGATE AND METHODS FOR THEIR PREPARATION

Nanoparticle complexes of paclitaxel, trastuzumab, and albumin

Heterodimeric antibodies that bind CD3 and tumor antigens

Targeting HER2 and HER3 with bispecific antibodies in cancerous cells

TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN

Method for producing polypeptide heteromultimer

Anti-DLL3 antibody drug conjugates

Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomib

Antibodies specific for claudin 6 (CLDN6)

Anti-B7-H1 antibodies for treating tumors

Fully human antibodies to BTLA

Anti-CD38 antibodies for treatment of acute myeloid leukemia

Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof

Pen-injector device containing anti-IL-6 antibodies

Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer

Heterodimeric antibodies that bind CD3 and CD38

Single-chain variable fragment anti-CD133 antibodies and uses thereof

Nucleolin antibodies

VEGFA/Ang2 Compounds

Molecular constructs with targeting and effector moieties

Peptide core-based multi-arm linkers

T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES

Human monoclonal antibodies specific for glypican-3 and use thereof

Antibodies to endoplasmin and their use

Targeting of podoplanin with lectin for use in the prevention and treatment of cancer

Molecular constructs for treating tumors

Bi-specific monovalent diabodies that are capable of binding CD123 and CD3, and uses thereof

Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof

Anti CD30 chimeric antigen receptor and its use

Means and methods for treating HBV infection and associated conditions

Combinatorial antibody libraries and uses thereof

Bispecific CD33 and CD3 binding proteins

CD70-BINDING PEPTIDES AND METHOD, PROCESS AND USE RELATING THERETO

Antibody which specifically reacts with human integrin A6B4

Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same

Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof

Antibodies against frizzled receptor

Monoclonal anti-GT 468 antibodies for treatment of cancer

Screening method for inhibitors of binding of zBR7R1 to CD155

Monoclonal antibodies against claudin-18 for treatment of cancer

Uses of antibodies to interleukin-6 in cancer treatment

Method for purifying antibodies using PBS

DE-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy

Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens

Humanized monoclonal antibodies and methods of use

Cytotoxic immunoglobulin

Anti-GD2 antibodies

T-cell redirecting bispecific antibodies for treatment of disease

Site-specific antibody conjugation methods and compositions

Synthetic library of specific binding molecules

Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof

MEDICAMENT COMPRISING ANTI-PHOSPHOLIPASE D4 ANTIBODY

Antibodies directed to HER-3 and uses thereof

Human bispecific EGFRvIII and CD3 antibody engaging molecules

Molecules that bind CD180, compositions and methods of use

Anti-FGFR3 antibodies and methods using same

Antibody multimerization technologies

Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists

Therapeutic Agent Comprising Humanized Anti-Epiregulin Antibody as Active Ingredient for Non-Small-Cell Lung Carcinoma Excluding Adenocarcinoma

Trimeric antigen binding molecules

Binding molecules specific for HER3 and uses thereof

Anti-B7-H4 antibodies and immunoconjugates

Diagnosis and therapy of cancer involving cancer stem cells

Insertable variable fragments of antibodies and modified A1-A2 domains of NKG2D ligands

BCL-XL Inhibitory Compounds and Antibody Drug Conjugates Including the Same

Antibodies for epidermal growth factor receptor 3 (HER3)

Immunopotentiative composition

Antibody binding sites specific for EGFRvIII

METHOD FOR INHIBITING CELL GROWTH USING ANTI-ERBB-3 ANTIBODIES

Fusion protein to target and treat acute myeloid leukemia cells

Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)

Anti-NGF antibodies and methods using same

METHODS, COMPOSITIONS AND APPARATUSES FOR FACILITATING REGENERATION

Methods of delivering DLL3 antibody drug conjugates

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease

Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof

Development of masked therapeutic antibodies to limit off-target effects

Anti-ErbB3 antibodies and uses thereof

Methods for controlling fucosylation levels in proteins

Humanized anti-OX40 antibodies and uses thereof

Therapeutic CD47 antibodies

Therapeutic CD47 antibodies

Antibody drug conjugates

Anti CD37 antibodies

Antibody-drug conjugate having improved stability and use thereof

Compositions including triciribine and trastuzumab and methods of use thereof

Methods and systems for predicting misfolded protein epitopes

Antigen binding protein and its use as addressing product for the treatment of cancer

HER2-specific monoclonal antibodies and conjugates thereof

Cysteine engineered antibodies and conjugates

Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same

Glycan-interacting compounds and methods of use

Antibodies to the B12-transcobalamin receptor

Anti-IL-6/IL-6R antibodies

KIR3DL2 IS A BIOMARKER AND A THERAPEUTIC TARGET USEFUL FOR RESPECTIVELY PREVENTING AND TREATING A SUBSET OF CUTANEOUS AND NON-CUTANEOUS PERIPHERAL T-CELL LYMPHOMAS

Antibody neutralizers of human granulocyte macrophage colony stimulating factor

Anti-nodal antibodies and methods of using same

Combining Radioimmunotherapy and Antibody-Drug Conjugates for Improved Cancer Therapy

Interferon lambda-antibody complexes

Anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer

Anti-CS1 antibodies and antibody drug conjugates

Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same

Method for producing antibody using “naked” expression vector expressing type II transmembrane fusion protein

Single domain antibodies directed against STAT3

SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST INTRACELLULAR ANTIGENS

Single domain antibodies directed against KRAS

Anti-CSPG4 fusions with interferon for the treatment of malignancy

Heterodimeric bispecific antibodies

Use of antibodies or antigen-binding fragments thereof that specifically bind semaphorin-4D to increase tumor infiltrating leukocyte frequency

CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

CD20 Antibodies and Uses Thereof

Targeting agent antibody conjugates and uses thereof

Single domain antibodies directed against TNF-alpha

Antitumor peptide derived from a complementarity determining region of a humanized monoclonal antibody to NAP12B transporter

Anti-CEACAM5 antibodies and uses thereof

RSPO3 binding agents and uses thereof

VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS

Antibody against peptide encoded by Exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same

Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same

Therapeutic antibodies against ROR-1 protein and methods for use of same

Humanization of rabbit antibodies using a universal antibody framework

Anti-HER2 antibodies and immunoconjugates

Treatment of cancer using a CD33 chimeric antigen receptor

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Conjugates comprising cell-binding agents and cytotoxic agents

Prediction of effect of a c-Met inhibitor using mutation of KRAS or BRAF

Polypeptide, anti-VEGF antibody, and anti-c-Met/anti-VEGF bispecific antibodies comprising the same

Construction and application of bispecific antibody EpCAM×CD3

Binding proteins specific for insulin-like growth factors and uses thereof

Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy

Bispecific HER2 and HER3 antigen binding constructs

mAB 2 anti-Met antibody

Methods for enhancing anti-tumor antibody therapy

CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases

Folate receptor 1 antibodies and immunoconjugates and uses thereof

ANTIGEN BINDING MOLECULES WITH INCREASED Fc RECEPTOR BINDING AFFINITY AND EFFECTOR FUNCTION

Isoform specific anti-HER4 antibodies

DNA encoding an anti-CD40 IgG2 antibody having amino acid mutations

CS1-specific chimeric antigen receptor engineered immune effector cells

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Methods for treating neoplasia

Cytotoxic and anti-mitotic compounds, and methods of using the same

Targeting O-acetylated GD2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer

Anti-DR5 antibodies, polynucleotides and methods

Treatment of cancer using a CD123 chimeric antigen receptor

Isolation of therapeutic target specific VNAR domains to ICOSL

Notch pathway inhibition

PD-1 antibodies

SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES

Human antibody drug conjugates against tissue factor

Markers of acute myeloid leukemia stem cells

Anti-FOLR1 antibody

Folate receptor 1 antibodies and immunoconjugates and uses thereof

Therapeutic DLL4 binding proteins

Anti-c-Met/anti-Ang2 bispecific antibody

METHODS OF TREATMENT FOR NEUROMYELITIS OPTICA

MONOCLONAL ANTIBODY CAPABLE OF BINDING TO ANEXELEKTO, AND USE THEREOF

Anti-human TROP-2 antibody having anti-tumor activity in vivo

Anti-CD276 polypeptides, proteins, and chimeric antigen receptors

Antibodies to a non-ligand binding region of at least two NOTCH receptors

Nucleic acids encoding antibodies against human CSF-1R

Immunological compositions as cancer therapeutics

Compositions and methods relating to inhibiting cancer cell growth and/or proliferation

Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy

DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

Antigen binding proteins

Antibodies and methods for treating estrogen receptor-associated diseases

Antibodies that bind colony stimulating factor 1 receptor (CSF1R)

Therapeutic peptides